Personalized Ophthalmology Therapies Market Report 2026

The personalized ophthalmology therapies market size has grown rapidly in recent years. It will grow from $3.23 billion in 2025 to $3.69 billion in 2026 at a compound annual growth rate (CAGR) of 14.2%. The growth in the historic period can be attributed to advancements in retinal disease research, increasing prevalence of chronic eye disorders, expansion of ophthalmology specialty clinics, improvements in ocular imaging technologies, growth in clinical trial activity for eye diseases.

The personalized ophthalmology therapies market size is expected to see rapid growth in the next few years. It will grow to $6.22 billion in 2030 at a compound annual growth rate (CAGR) of 14%. The growth in the forecast period can be attributed to increasing approvals of gene and cell therapies, rising investments in precision ophthalmology research, expansion of personalized treatment protocols, growing adoption of advanced drug delivery platforms, increasing demand for long-term vision preservation solutions. Major trends in the forecast period include increasing development of gene-based ophthalmic therapies, rising adoption of biomarker-guided treatment approaches, growing use of advanced retinal imaging for therapy selection, expansion of targeted drug delivery systems, enhanced focus on personalized disease management.

The growing prevalence of chronic vision disorders is expected to propel the growth of the personalized ophthalmology therapies market going forward. Chronic vision disorders are increasing due to rising diabetes prevalence. Personalized ophthalmology therapies tailor treatment based on genetic and molecular profiles, improving outcomes. For instance, diabetic retinopathy cases are projected to increase significantly by 2050. Therefore, growing chronic vision disorders are driving the personalized ophthalmology therapies market.

Leading companies operating in the personalized ophthalmology therapies market are focusing on developing advanced solutions, such as one-time intravitreal gene therapies, to reduce patient burden and minimize risks associated with repeated injections. One-time intravitreal gene therapies involve a single injection into the vitreous cavity of the eye to deliver genetic material that targets or modifies underlying ocular disorders, providing sustained therapeutic effects. For instance, in July 2025, Sanofi, a France-based pharmaceutical and healthcare company, announced that the US Food and Drug Administration (FDA) granted fast track designation to SAR446597. This single-dose intravitreal gene therapy is intended to treat geographic atrophy (GA) caused by age-related macular degeneration (AMD) and received fast track status to accelerate development and regulatory review for a serious condition with unmet medical needs. The therapy delivers genetic material encoding two antibody fragments that inhibit C1s in the classical complement pathway and factor Bb in the alternative pathway. This dual-target mechanism is designed to provide long-lasting complement suppression in the retina while reducing the need for repeated intravitreal injections.

In December 2024, EssilorLuxottica S.A., a France-based healthcare company, acquired Espansione Group for an undisclosed amount. Through this acquisition, EssilorLuxottica aimed to expand its med-tech portfolio and strengthen its offering of advanced vision-care instruments and certified medical technologies. Espansione Group S.p.A. is an Italy-based med-tech company specializing in personalized ophthalmology therapies.

Major companies operating in the personalized ophthalmology therapies market are Roche Holding AG, Novartis AG, Regeneron Pharmaceuticals Inc., Alcon Inc., Genentech Inc., Bausch + Lomb Corporation, Johnson & Johnson Vision Care Inc., Carl Zeiss Meditec AG, Santen Pharmaceutical Co. Ltd., Ocular Therapeutix Inc., EyePoint Pharmaceuticals Inc., Senju Pharmaceutical Co. Ltd., MeiraGTx Ltd., Beacon Therapeutics, Clearside Biomedical Inc., Adverum Biotechnologies Inc., Ocugen Inc., GenSight Biologics, Nanoscope Therapeutics Inc., 4D Molecular Therapeutics Inc., Coave Therapeutics.

North America was the largest region in the personalized ophthalmology therapies market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the personalized ophthalmology therapies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the personalized ophthalmology therapies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the personalized ophthalmology therapies market by increasing costs of imported biologics, gene therapy vectors, specialized delivery devices, and advanced diagnostic equipment. Healthcare providers and therapy developers in North America and Europe are most affected due to reliance on imported high-value components, while Asia-Pacific faces higher costs in therapy manufacturing and distribution. These tariffs are increasing treatment costs and slowing commercialization timelines. At the same time, they are encouraging regional manufacturing of ophthalmic therapeutics, localized supply chains, and investment in domestic biopharmaceutical production capabilities.

The personalized ophthalmology therapies market research report is one of a series of new reports that provides personalized ophthalmology therapies market statistics, including personalized ophthalmology therapies industry global market size, regional shares, competitors with a personalized ophthalmology therapies market share, detailed personalized ophthalmology therapies market segments, market trends and opportunities, and any further data you may need to thrive in the personalized ophthalmology therapies industry. This personalized ophthalmology therapies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Personalized ophthalmology therapies involve tailored treatment strategies for eye diseases and vision disorders that are customized based on an individual patient’s genetic makeup, molecular features, lifestyle factors, and clinical condition. These therapies utilize advancements in genomics, biomarker evaluation, imaging technologies, and precision medicine to optimize treatment selection, dosing, or surgical approaches for conditions such as age-related macular degeneration (AMD), glaucoma, diabetic retinopathy, and inherited retinal disorders.

The primary types of personalized ophthalmology therapies include gene therapy, cell therapy, pharmacogenomics, targeted drug delivery, and others. Gene therapy in ophthalmology involves modifying or introducing genetic material into patient cells to treat eye diseases caused by genetic abnormalities. It is applied in conditions such as age-related macular degeneration, diabetic retinopathy, glaucoma, retinitis pigmentosa, and others and is used by end-users including hospitals, specialty clinics, research institutes, and others.

The personalized ophthalmology therapies market includes revenues earned by entities by providing services such as molecular profiling, biomarker identification, patient data integration services, and disease risk assessment. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.